Chris Shibutani
Stock Analyst at Goldman Sachs
(3.19)
# 1,123
Out of 5,139 analysts
96
Total ratings
54%
Success rate
12.29%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.59 | +114.64% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $9.62 | -68.81% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $15.96 | -6.02% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $31.63 | +1.17% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $109.00 | +25.69% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $20.52 | +60.82% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $464.93 | -35.04% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $39.55 | +28.95% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $218.66 | -29.11% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $14.30 | -72.03% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $8.76 | +128.31% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,038.40 | -30.37% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $16.79 | +54.85% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $132.39 | +15.57% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $214.35 | -19.29% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $37.68 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $55.26 | +24.86% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.44 | -33.13% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $120.28 | -80.88% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.89 | +259.97% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $69.54 | -25.22% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.65 | +133.92% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.00 | +63.64% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $13.01 | +30.67% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.58 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.75 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.37 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.59
Upside: +114.64%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $9.62
Upside: -68.81%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $15.96
Upside: -6.02%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $31.63
Upside: +1.17%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $109.00
Upside: +25.69%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $20.52
Upside: +60.82%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $464.93
Upside: -35.04%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $39.55
Upside: +28.95%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $218.66
Upside: -29.11%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $14.30
Upside: -72.03%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $8.76
Upside: +128.31%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,038.40
Upside: -30.37%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $16.79
Upside: +54.85%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $132.39
Upside: +15.57%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $214.35
Upside: -19.29%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $37.68
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $55.26
Upside: +24.86%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.44
Upside: -33.13%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $120.28
Upside: -80.88%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $13.89
Upside: +259.97%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $69.54
Upside: -25.22%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.65
Upside: +133.92%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.00
Upside: +63.64%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $13.01
Upside: +30.67%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.58
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.75
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.37
Upside: -